Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Opts Not to Renew Contract with Premier

NEW YORK (GenomeWeb) – Cepheid said after the close of the market Wednesday that it has decided not to renew its group purchasing contract with Premier.

The Sunnyvale, Calif.-based molecular diagnostics firm said that its current contract with Premier will end on Sept. 30, 2014. It said that customers can order products through other group purchasing organizations with which the firm has contracted, including Amerinet, Baycare, HPA, MedAssets, Novation, ROi, and HealthTrust, or directly from the firm.

"Cepheid has always recognized and supported the value of group purchasing organizations and the role they play in driving the adoption of innovative technologies to improve patient care while also delivering attractive pricing for their members," Jim Post, Cepheid's executive vice president of North America Commercial Operations, said in a statement. "However, in this case, we were not able to agree on the appropriate level of fees paid by Cepheid relative to the value delivered by this particular contract."

Cepheid added that it expects no customer or revenue impact as a result of not renewing the contract.

Premier serves approximately 3,000 hospitals and 110,000 other non-acute healthcare providers in the US.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more